Life Science and pharma
Practical advice
fitted to the rapidly changing industry
Enterprises from the Life Science sector do not need “ordinary” tax and legal support. They expect advice on the specifics of this sector. That is what we provide to our clients.
ALTO advisors support, among others, pharmacies, producers of supplements as well as Polish and international pharmaceutical companies.
We have experience in cooperating with companies offering innovative solutions in the field of collecting, storing and conducting therapy with the use of biological materials, as well as CRO companies conducting clinical trials. Such a wide range of activities allows us to state with full responsibility that we know the Life Science industry and its needs.
Our team provides clients with ongoing tax advice in the area of CIT, VAT, PIT and ZUS, as well as supports them in the design and implementation of internal procedures – including the field of marketing activities. We also offer consulting services in the field of transfer pricing.
In the course of our practice, we have carried out many complex projects, including structuring the operations of a company from an international pharmaceutical group that was taking over a competitor’s business. Our advisory project included the impact assessment of the acquisition on the functional profile of the pharmaceutical company and the implementation of a new transfer pricing policy. We know what to pay special attention to and how to work with clients from the Life sciences industry to help them achieve their business goals.
We are distinguished by extensive industry knowledge, many years of experience and a comprehensive approach. If you are looking for consultancy tailored to the needs of your company, check the list of our services for pharmaceutical companies and life sciences.
ALTOstratus
We enable clients to use the tools and applications we have created. They allow you to operate more comfortably and safer safely on a daily basis.
Your team
Case studies
Tax
200% write-off under R&D relief vs. an individual interpretation